<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00409773</url>
  </required_header>
  <id_info>
    <org_study_id>0653A-107</org_study_id>
    <secondary_id>2006_527</secondary_id>
    <nct_id>NCT00409773</nct_id>
  </id_info>
  <brief_title>Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients With Metabolic Syndrome and Hypercholesterolemia at High Risk for Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A 6-week clinical trial in patients with metabolic syndrome and hypercholesterolemia at high
      risk for coronary heart disease to study the effects of ezetimibe/simvastatin and
      atorvastatin on lipids.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol(mg/dL) at Week 6</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglyceride (TG) (mg/dL) at Week 6</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 6</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non- High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol (VLDL-C) at Week 6</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein- B (Apo-B) at Week 6</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein-A1 (Apo-A1) at Week 6</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total-Cholesterol: High Density Lipoprotein-Cholesterol (Total-C:HDL- C) at Week 6</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Low Density Lipoprotein Cholesterol: High Density Lipoprotein Cholesterol (LDL-C: HDL-C) at Week 6</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein-B: Apolipoprotein-A1 (Apo-B:Apo-A1) at Week 6</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol: High Density Lipoprotein Cholesterol (Non-HDL-C:HDL-C) at Week 6</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 6 in Patients With Atherosclerotic Vascular Disease (AVD)</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 6 in Patients Without Atherosclerotic Vascular Disease (AVD)</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High-Sensitivity C-reactive (Hs-CRP) (mg/dL) at Week 6</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1143</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 1: drug + comparator + Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 2: drug + comparator + Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 3: drug + comparator + Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 4: drug + comparator + Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 5: drug + comparator + Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe (+) simvastatin</intervention_name>
    <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <other_name>MK0653A</other_name>
    <other_name>Vytorin速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: atorvastatin calcium</intervention_name>
    <description>Atorvastatin will be supplied in 10mg, 20mg and 40mg tablets.
Each patient will receive 1 active treatment dose &amp; 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <other_name>Lipitor 速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo (unspecified)</intervention_name>
    <description>Atorvastatin Placebo will be supplied in 10mg, 20mg and 40mg tablets.
ezetimibe/simvastatin Placebo will be supplied in 10/20mg and 10/40mg combination tablets.
Each patient will receive 1 active treatment dose &amp; 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 to 79 years of age with metabolic syndrome and hypercholesterolemia at
             high risk for coronary heart disease (CHD) with LDL-C above 70 mg/dL or 100 mg/dL
             depending on their CHD risk category

        Exclusion Criteria:

          -  A condition which, in the opinion of the investigator, pose a risk to the patient or
             interfere with participating in the study

          -  Patient is likely to be greater than 20% noncompliant in taking study medications

          -  Patients with chronic medical conditions

          -  Patients with unstable doses of medications

          -  Pregnant or lactating women, women intending to become pregnant

          -  Patient is currently receiving prescription therapy with statins or other
             lipid-altering medications

          -  Patient with Type 1 or Type 2 diabetes mellitus that is poorly controlled, newly
             diagnosed, or is taking new or recently adjusted antidiabetic pharmacotherapy (with
             the exception of +/- 10 units of insulin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Colombia</country>
    <country>Ecuador</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>(MedWatch - FDA maintained medical product safety Information)</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>(Merck: Patient &amp; Caregiver U.S. Product Web Site)</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2006</study_first_submitted>
  <study_first_submitted_qc>December 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2006</study_first_posted>
  <results_first_submitted>June 16, 2009</results_first_submitted>
  <results_first_submitted_qc>June 17, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2009</results_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase III
First Patient In 06-Feb-2007:; Last Patient Last Visit 16-Jul-2008
110 centers worldwide (International, 12 countries)
Eligible patients include drug-na誰ve patients or patients rendered na誰ve with the appropriate prior washout at moderately high or high risk for coronary heart disease.</recruitment_details>
      <pre_assignment_details>Patients were randomized to 1 of 5 treatment groups: ezetimibe/simvastatin combination tablet or atorvastatin alone for 6 weeks stratified according to their baseline risk category stratum (high risk patients with atherosclerotic vascular disease or high risk patients without atherosclerotic vascular disease and moderately high risk patients).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atorva 10 mg</title>
          <description>Atorvastatin 10 mg once daily for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>EZ/Simva 10 mg/20 mg</title>
          <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg</description>
        </group>
        <group group_id="P3">
          <title>Atorva 20mg</title>
          <description>Atorvastatin 20 mg once daily for 6 weeks</description>
        </group>
        <group group_id="P4">
          <title>EZ/Simva 10 mg/40 mg</title>
          <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/40 mg</description>
        </group>
        <group group_id="P5">
          <title>Atorva 40 mg</title>
          <description>Atorvastatin 40 mg once daily for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="229"/>
                <participants group_id="P2" count="229"/>
                <participants group_id="P3" count="229"/>
                <participants group_id="P4" count="228"/>
                <participants group_id="P5" count="228"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="222"/>
                <participants group_id="P3" count="220"/>
                <participants group_id="P4" count="216"/>
                <participants group_id="P5" count="218"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Eligibility</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atorva 10 mg</title>
          <description>Atorvastatin 10 mg once daily for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>EZ/Simva 10 mg/20 mg</title>
          <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg</description>
        </group>
        <group group_id="B3">
          <title>Atorva 20mg</title>
          <description>Atorvastatin 20 mg once daily for 6 weeks</description>
        </group>
        <group group_id="B4">
          <title>EZ/Simva 10 mg/40 mg</title>
          <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/40 mg</description>
        </group>
        <group group_id="B5">
          <title>Atorva 40 mg</title>
          <description>Atorvastatin 40 mg once daily for 6 weeks</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="229"/>
            <count group_id="B2" value="229"/>
            <count group_id="B3" value="229"/>
            <count group_id="B4" value="228"/>
            <count group_id="B5" value="228"/>
            <count group_id="B6" value="1143"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.7" lower_limit="31" upper_limit="79"/>
                    <measurement group_id="B2" value="59.7" lower_limit="32" upper_limit="78"/>
                    <measurement group_id="B3" value="58.2" lower_limit="33" upper_limit="78"/>
                    <measurement group_id="B4" value="59.5" lower_limit="28" upper_limit="80"/>
                    <measurement group_id="B5" value="58.4" lower_limit="28" upper_limit="79"/>
                    <measurement group_id="B6" value="59.1" lower_limit="28" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="104"/>
                    <measurement group_id="B5" value="104"/>
                    <measurement group_id="B6" value="498"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="124"/>
                    <measurement group_id="B5" value="124"/>
                    <measurement group_id="B6" value="645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="177"/>
                    <measurement group_id="B4" value="171"/>
                    <measurement group_id="B5" value="167"/>
                    <measurement group_id="B6" value="856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6</title>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg</title>
            <description>Atorvastatin 10 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>EZ/Simva 10 mg/20 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg</description>
          </group>
          <group group_id="O3">
            <title>Atorva 20mg</title>
            <description>Atorvastatin 20 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>EZ/Simva 10 mg/40 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/40 mg</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="215"/>
                <count group_id="O4" value="217"/>
                <count group_id="O5" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.5" lower_limit="-38.9" upper_limit="-34.0"/>
                    <measurement group_id="O2" value="-49.6" lower_limit="-52.0" upper_limit="-47.2"/>
                    <measurement group_id="O3" value="-39.4" lower_limit="-41.8" upper_limit="-36.9"/>
                    <measurement group_id="O4" value="-53.9" lower_limit="-56.4" upper_limit="-51.5"/>
                    <measurement group_id="O5" value="-46.0" lower_limit="-48.4" upper_limit="-43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-16.5</ci_lower_limit>
            <ci_upper_limit>-9.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-13.6</ci_lower_limit>
            <ci_upper_limit>-6.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.3</ci_lower_limit>
            <ci_upper_limit>-4.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol(mg/dL) at Week 6</title>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg</title>
            <description>Atorvastatin 10 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>EZ/Simva 10 mg/20 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg</description>
          </group>
          <group group_id="O3">
            <title>Atorva 20mg</title>
            <description>Atorvastatin 20 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>EZ/Simva 10 mg/40 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/40 mg</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol(mg/dL) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="216"/>
                <count group_id="O4" value="217"/>
                <count group_id="O5" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.5" lower_limit="-28.2" upper_limit="-24.7"/>
                    <measurement group_id="O2" value="-33.7" lower_limit="-35.4" upper_limit="-31.9"/>
                    <measurement group_id="O3" value="-28.3" lower_limit="-30.1" upper_limit="-26.6"/>
                    <measurement group_id="O4" value="-37.3" lower_limit="-39.0" upper_limit="-35.5"/>
                    <measurement group_id="O5" value="-32.8" lower_limit="-34.6" upper_limit="-31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.6</ci_lower_limit>
            <ci_upper_limit>-4.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.8</ci_lower_limit>
            <ci_upper_limit>-2.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>-2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglyceride (TG) (mg/dL) at Week 6</title>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg</title>
            <description>Atorvastatin 10 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>EZ/Simva 10 mg/20 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg</description>
          </group>
          <group group_id="O3">
            <title>Atorva 20mg</title>
            <description>Atorvastatin 20 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>EZ/Simva 10 mg/40 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/40 mg</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglyceride (TG) (mg/dL) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="216"/>
                <count group_id="O4" value="217"/>
                <count group_id="O5" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.7" lower_limit="-25.0" upper_limit="-17.9"/>
                    <measurement group_id="O2" value="-23.3" lower_limit="-26.9" upper_limit="-18.2"/>
                    <measurement group_id="O3" value="-27.5" lower_limit="-30.8" upper_limit="-22.4"/>
                    <measurement group_id="O4" value="-29.5" lower_limit="-32.5" upper_limit="-25.0"/>
                    <measurement group_id="O5" value="-30.0" lower_limit="-34.2" upper_limit="-26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.690</p_value>
            <method>Non-parametric ANOVA</method>
            <method_desc>ANOVA using normal scores (Tukey method) based on ranks with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.4</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.200</p_value>
            <method>Non-parametric ANOVA</method>
            <method_desc>ANOVA using normal scores (Tukey method) based on ranks with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>7.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.480</p_value>
            <method>Non-parametric ANOVA</method>
            <method_desc>ANOVA using normal scores (Tukey method) based on ranks with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 6</title>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg</title>
            <description>Atorvastatin 10 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>EZ/Simva 10 mg/20 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg</description>
          </group>
          <group group_id="O3">
            <title>Atorva 20mg</title>
            <description>Atorvastatin 20 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>EZ/Simva 10 mg/40 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/40 mg</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="216"/>
                <count group_id="O4" value="217"/>
                <count group_id="O5" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="1.5" upper_limit="5.3"/>
                    <measurement group_id="O2" value="6.8" lower_limit="4.9" upper_limit="8.7"/>
                    <measurement group_id="O3" value="5.6" lower_limit="3.7" upper_limit="7.5"/>
                    <measurement group_id="O4" value="8.8" lower_limit="6.9" upper_limit="10.7"/>
                    <measurement group_id="O5" value="4.9" lower_limit="3.0" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>6.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.378</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>6.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non- High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6</title>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg</title>
            <description>Atorvastatin 10 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>EZ/Simva 10 mg/20 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg</description>
          </group>
          <group group_id="O3">
            <title>Atorva 20mg</title>
            <description>Atorvastatin 20 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>EZ/Simva 10 mg/40 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/40 mg</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non- High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="216"/>
                <count group_id="O4" value="217"/>
                <count group_id="O5" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.5" lower_limit="-35.6" upper_limit="-31.3"/>
                    <measurement group_id="O2" value="-43.8" lower_limit="-45.9" upper_limit="-41.7"/>
                    <measurement group_id="O3" value="-36.5" lower_limit="-38.6" upper_limit="-34.4"/>
                    <measurement group_id="O4" value="-48.3" lower_limit="-50.5" upper_limit="-46.2"/>
                    <measurement group_id="O5" value="-41.4" lower_limit="-43.6" upper_limit="-39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-13.3</ci_lower_limit>
            <ci_upper_limit>-7.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.2</ci_lower_limit>
            <ci_upper_limit>-4.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.9</ci_lower_limit>
            <ci_upper_limit>-3.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol (VLDL-C) at Week 6</title>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg</title>
            <description>Atorvastatin 10 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>EZ/Simva 10 mg/20 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg</description>
          </group>
          <group group_id="O3">
            <title>Atorva 20mg</title>
            <description>Atorvastatin 20 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>EZ/Simva 10 mg/40 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/40 mg</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol (VLDL-C) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="217"/>
                <count group_id="O3" value="209"/>
                <count group_id="O4" value="214"/>
                <count group_id="O5" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.7" lower_limit="-21.4" upper_limit="-14.0"/>
                    <measurement group_id="O2" value="-18.3" lower_limit="-22.0" upper_limit="-14.7"/>
                    <measurement group_id="O3" value="-21.6" lower_limit="-25.3" upper_limit="-17.8"/>
                    <measurement group_id="O4" value="-23.4" lower_limit="-27.1" upper_limit="-19.7"/>
                    <measurement group_id="O5" value="-22.7" lower_limit="-26.4" upper_limit="-19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.809</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.7</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.217</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>8.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.796</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein- B (Apo-B) at Week 6</title>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg</title>
            <description>Atorvastatin 10 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>EZ/Simva 10 mg/20 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg</description>
          </group>
          <group group_id="O3">
            <title>Atorva 20mg</title>
            <description>Atorvastatin 20 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>EZ/Simva 10 mg/40 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/40 mg</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein- B (Apo-B) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="218"/>
                <count group_id="O3" value="213"/>
                <count group_id="O4" value="214"/>
                <count group_id="O5" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.9" lower_limit="-29.9" upper_limit="-25.9"/>
                    <measurement group_id="O2" value="-37.2" lower_limit="-39.2" upper_limit="-35.3"/>
                    <measurement group_id="O3" value="-31.9" lower_limit="-33.9" upper_limit="-29.9"/>
                    <measurement group_id="O4" value="-41.1" lower_limit="-43.1" upper_limit="-39.1"/>
                    <measurement group_id="O5" value="-35.8" lower_limit="-37.8" upper_limit="-33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-12.1</ci_lower_limit>
            <ci_upper_limit>-6.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.1</ci_lower_limit>
            <ci_upper_limit>-2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.0</ci_lower_limit>
            <ci_upper_limit>-2.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein-A1 (Apo-A1) at Week 6</title>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg</title>
            <description>Atorvastatin 10 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>EZ/Simva 10 mg/20 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg</description>
          </group>
          <group group_id="O3">
            <title>Atorva 20mg</title>
            <description>Atorvastatin 20 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>EZ/Simva 10 mg/40 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/40 mg</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein-A1 (Apo-A1) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="213"/>
                <count group_id="O4" value="214"/>
                <count group_id="O5" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="-1.0" upper_limit="2.5"/>
                    <measurement group_id="O2" value="3.2" lower_limit="1.5" upper_limit="4.9"/>
                    <measurement group_id="O3" value="1.0" lower_limit="-0.7" upper_limit="2.7"/>
                    <measurement group_id="O4" value="3.0" lower_limit="1.3" upper_limit="4.7"/>
                    <measurement group_id="O5" value="1.4" lower_limit="-0.3" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>4.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.0</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total-Cholesterol: High Density Lipoprotein-Cholesterol (Total-C:HDL- C) at Week 6</title>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg</title>
            <description>Atorvastatin 10 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>EZ/Simva 10 mg/20 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg</description>
          </group>
          <group group_id="O3">
            <title>Atorva 20mg</title>
            <description>Atorvastatin 20 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>EZ/Simva 10 mg/40 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/40 mg</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total-Cholesterol: High Density Lipoprotein-Cholesterol (Total-C:HDL- C) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="216"/>
                <count group_id="O4" value="217"/>
                <count group_id="O5" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.1" lower_limit="-30.1" upper_limit="-26.0"/>
                    <measurement group_id="O2" value="-36.9" lower_limit="-38.9" upper_limit="-34.8"/>
                    <measurement group_id="O3" value="-31.5" lower_limit="-33.6" upper_limit="-29.5"/>
                    <measurement group_id="O4" value="-41.2" lower_limit="-43.2" upper_limit="-39.1"/>
                    <measurement group_id="O5" value="-35.3" lower_limit="-37.3" upper_limit="-33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.6</ci_lower_limit>
            <ci_upper_limit>-6.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.2</ci_lower_limit>
            <ci_upper_limit>-2.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.7</ci_lower_limit>
            <ci_upper_limit>-3.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Low Density Lipoprotein Cholesterol: High Density Lipoprotein Cholesterol (LDL-C: HDL-C) at Week 6</title>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg</title>
            <description>Atorvastatin 10 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>EZ/Simva 10 mg/20 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg</description>
          </group>
          <group group_id="O3">
            <title>Atorva 20mg</title>
            <description>Atorvastatin 20 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>EZ/Simva 10 mg/40 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/40 mg</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low Density Lipoprotein Cholesterol: High Density Lipoprotein Cholesterol (LDL-C: HDL-C) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="215"/>
                <count group_id="O4" value="217"/>
                <count group_id="O5" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.8" lower_limit="-40.3" upper_limit="-35.2"/>
                    <measurement group_id="O2" value="-51.8" lower_limit="-54.3" upper_limit="-49.3"/>
                    <measurement group_id="O3" value="-42.1" lower_limit="-44.7" upper_limit="-39.6"/>
                    <measurement group_id="O4" value="-56.6" lower_limit="-59.2" upper_limit="-54.1"/>
                    <measurement group_id="O5" value="-48.2" lower_limit="-50.7" upper_limit="-45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-17.6</ci_lower_limit>
            <ci_upper_limit>-10.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-13.2</ci_lower_limit>
            <ci_upper_limit>-6.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-12.0</ci_lower_limit>
            <ci_upper_limit>-4.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein-B: Apolipoprotein-A1 (Apo-B:Apo-A1) at Week 6</title>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg</title>
            <description>Atorvastatin 10 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>EZ/Simva 10 mg/20 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg</description>
          </group>
          <group group_id="O3">
            <title>Atorva 20mg</title>
            <description>Atorvastatin 20 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>EZ/Simva 10 mg/40 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/40 mg</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein-B: Apolipoprotein-A1 (Apo-B:Apo-A1) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="218"/>
                <count group_id="O3" value="213"/>
                <count group_id="O4" value="214"/>
                <count group_id="O5" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.4" lower_limit="-29.6" upper_limit="-25.2"/>
                    <measurement group_id="O2" value="-38.4" lower_limit="-40.6" upper_limit="-36.2"/>
                    <measurement group_id="O3" value="-32.0" lower_limit="-34.2" upper_limit="-29.8"/>
                    <measurement group_id="O4" value="-41.9" lower_limit="-44.1" upper_limit="-39.7"/>
                    <measurement group_id="O5" value="-36.2" lower_limit="-38.4" upper_limit="-34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-14.0</ci_lower_limit>
            <ci_upper_limit>-8.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>-3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.7</ci_lower_limit>
            <ci_upper_limit>-2.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol: High Density Lipoprotein Cholesterol (Non-HDL-C:HDL-C) at Week 6</title>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg</title>
            <description>Atorvastatin 10 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>EZ/Simva 10 mg/20 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg</description>
          </group>
          <group group_id="O3">
            <title>Atorva 20mg</title>
            <description>Atorvastatin 20 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>EZ/Simva 10 mg/40 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/40 mg</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol: High Density Lipoprotein Cholesterol (Non-HDL-C:HDL-C) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="216"/>
                <count group_id="O4" value="217"/>
                <count group_id="O5" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.7" lower_limit="-37.2" upper_limit="-32.2"/>
                    <measurement group_id="O2" value="-46.2" lower_limit="-48.6" upper_limit="-43.7"/>
                    <measurement group_id="O3" value="-39.2" lower_limit="-41.7" upper_limit="-36.7"/>
                    <measurement group_id="O4" value="-51.2" lower_limit="-53.7" upper_limit="-48.7"/>
                    <measurement group_id="O5" value="-43.5" lower_limit="-46.0" upper_limit="-41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-15.0</ci_lower_limit>
            <ci_upper_limit>-8.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.4</ci_lower_limit>
            <ci_upper_limit>-3.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.2</ci_lower_limit>
            <ci_upper_limit>-4.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 6 in Patients With Atherosclerotic Vascular Disease (AVD)</title>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg</title>
            <description>Atorvastatin 10 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>EZ/Simva 10 mg/20 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg</description>
          </group>
          <group group_id="O3">
            <title>Atorva 20mg</title>
            <description>Atorvastatin 20 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>EZ/Simva 10 mg/40 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/40 mg</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 6 in Patients With Atherosclerotic Vascular Disease (AVD)</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.1" lower_limit="-41.4" upper_limit="-32.7"/>
                    <measurement group_id="O2" value="-48.7" lower_limit="-52.8" upper_limit="-44.6"/>
                    <measurement group_id="O3" value="-36.9" lower_limit="-41.5" upper_limit="-32.4"/>
                    <measurement group_id="O4" value="-56.1" lower_limit="-60.6" upper_limit="-51.7"/>
                    <measurement group_id="O5" value="-45.8" lower_limit="-50.2" upper_limit="-41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 6 in Patients Without Atherosclerotic Vascular Disease (AVD)</title>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg</title>
            <description>Atorvastatin 10 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>EZ/Simva 10 mg/20 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg</description>
          </group>
          <group group_id="O3">
            <title>Atorva 20mg</title>
            <description>Atorvastatin 20 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>EZ/Simva 10 mg/40 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/40 mg</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 6 in Patients Without Atherosclerotic Vascular Disease (AVD)</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="156"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.3" lower_limit="-39.1" upper_limit="-33.5"/>
                    <measurement group_id="O2" value="-50.1" lower_limit="-52.9" upper_limit="-47.2"/>
                    <measurement group_id="O3" value="-40.3" lower_limit="-43.1" upper_limit="-37.6"/>
                    <measurement group_id="O4" value="-53.2" lower_limit="-55.9" upper_limit="-50.4"/>
                    <measurement group_id="O5" value="-46.1" lower_limit="-48.9" upper_limit="-43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High-Sensitivity C-reactive (Hs-CRP) (mg/dL) at Week 6</title>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg</title>
            <description>Atorvastatin 10 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>EZ/Simva 10 mg/20 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg</description>
          </group>
          <group group_id="O3">
            <title>Atorva 20mg</title>
            <description>Atorvastatin 20 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>EZ/Simva 10 mg/40 mg</title>
            <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/40 mg</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High-Sensitivity C-reactive (Hs-CRP) (mg/dL) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="218"/>
                <count group_id="O3" value="210"/>
                <count group_id="O4" value="216"/>
                <count group_id="O5" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.8" lower_limit="-21.7" upper_limit="-10.6"/>
                    <measurement group_id="O2" value="-17.2" lower_limit="-24.1" upper_limit="-12.5"/>
                    <measurement group_id="O3" value="-22.4" lower_limit="-26.1" upper_limit="-14.6"/>
                    <measurement group_id="O4" value="-27.6" lower_limit="-33.3" upper_limit="-21.4"/>
                    <measurement group_id="O5" value="-30.0" lower_limit="-33.3" upper_limit="-25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.420</p_value>
            <method>Non-parametric ANOVA</method>
            <method_desc>ANOVA using normal scores (Tukey method) based on ranks with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.0</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.555</p_value>
            <method>Non-parametric ANOVA</method>
            <method_desc>ANOVA using normal scores (Tukey method) based on ranks with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>7.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.410</p_value>
            <method>Non-parametric ANOVA</method>
            <method_desc>ANOVA using normal scores (Tukey method) based on ranks with terms for treatment and baseline risk stratum</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.1</ci_lower_limit>
            <ci_upper_limit>9.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Atorva 10 mg</title>
          <description>Atorvastatin 10 mg once daily for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>EZ/Simva 10 mg/20 mg</title>
          <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg</description>
        </group>
        <group group_id="E3">
          <title>Atorva 20mg</title>
          <description>Atorvastatin 20 mg once daily for 6 weeks</description>
        </group>
        <group group_id="E4">
          <title>EZ/Simva 10 mg/40 mg</title>
          <description>Ezetimibe (+) simvastatin combination tablet at doses of 10/40 mg</description>
        </group>
        <group group_id="E5">
          <title>Atorva 40 mg</title>
          <description>Atorvastatin 40 mg once daily for 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4"/>
                <counts group_id="E2" subjects_affected="0"/>
                <counts group_id="E3" subjects_affected="1"/>
                <counts group_id="E4" subjects_affected="1"/>
                <counts group_id="E5" subjects_affected="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Second Degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Ischaemic Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21"/>
                <counts group_id="E2" subjects_affected="14"/>
                <counts group_id="E3" subjects_affected="22"/>
                <counts group_id="E4" subjects_affected="13"/>
                <counts group_id="E5" subjects_affected="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Any Gastrointestinal Disorders</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Abdominal Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Any General Disorders And Administration Site Conditions</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Any Infections and Infestations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Any Musculoskeletal And Connective Tissue Disorders</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Any Nervous System Disorders</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Any Vascular Disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>15 patients were randomized but not treated. Since these patients were not treated no Adverse Event Data was collected.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

